Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.

NCT01485926 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT01485926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01485926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.
Lead sponsor
Cancer Trials Ireland
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2010
Completion date
May 31, 2018
Enrollment
120 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer